[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:immunoglobulin-heavy-chain-variable-domain":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Immunoglobulin Heavy Chain Variable Domain",4,[7,15,22,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07566364","Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD",[11],"Phase 2","RECRUITING","2026-08-26T02:19:03.581490Z","2026-05-13T02:55:06.731598Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT03219450","A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.",[19],"Phase 1","2026-08-26T02:15:02.712396Z","2026-05-05T02:43:29.583843Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT04169737","Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[11],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:28.287166Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":33,"content_modified":34},"NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies",[32],"Phase 1\u002FPhase 2","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.644953Z"]